Skip to main content
OpenTrials
Completed

NCT Number: NCT01618344

Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer

To explore use of a smart-phone medication reminder application to promote adherence to oral medications by AYA with cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year–29 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

About this study

Non-adherence to oral medications is a prevalent problem in adolescents and young adults (AYA) with cancer that may impact both survival and quality of life while on treatment. The purpose of this study is to explore use of a smart-phone medication reminder application to promote adherence to oral medications by AYA with cancer. The study's primary aim is to explore the feasibility and acceptability of using a smart-phone medication reminder application to promote adherence to oral medications by AYA with cancer as well as to characterize application use. Secondary aims include: 1) to obtain initial estimates of intervention effect- measured by pre-intervention to post-intervention differences in perceived behavioral control for adherence, intention to adhere, and adherence behavior - to inform design of a future trial powered to detect a clinically significant effect of smart-phone medication reminder application use on adherence to oral medications; and 2) to examine the relationships among perceived behavioral control for adherence, intention to adhere, and adherence behavior. A pre-post single group design will be used. Data will be collected weekly for 4 weeks before introduction of the intervention and for 8 weeks following introduction of the intervention. Analytic approaches will include descriptive statistics and generalized estimating equation (GEE) modeling.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1)15-29 year olds receiving treatment for any type of cancer, either primary or recurrent/relapsed disease.

  • Patient has completed at least one month of therapy

3)Patient is expected to remain on therapy for 3 month duration of study

  • Patient has an iPhone, iPad, or iTouch running iOS 4.0 or later
  • Patient is willing to use a smart-phone medication reminder application-

Exclusion criteria

1)Patients who are unable to speak/read/write English as required for use of smart-phone medication reminder application and completion of study measures.

Treatment and study plan

Primary outcomes

  1. Feasibility and Acceptability of Using a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by AYA With Cancer.

    Time frame: ongoing study weeks 5-12

    Feasibility was assessed through participants' application usage and responses to self-reported questions about their use of the application. Acceptability was assessed through participants' perceived ease of use and perceived usefulness of the application.

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Collaborators

  • Oncology Nursing Society

Registry information

Official study title

Use of a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by Adolescents and Young Adults(AYA) With Cancer

Important dates

Study start
2012
Primary completion
2016
Study completion
2017
First posted
Jun 13, 2012
Registry last updated
Nov 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.